ForYou Medical Secures Strategic Investment from Novo Holdings, Partnering to Drive Global Growth in China's Advanced Wound Care

Singapore, 10 September 2026 — ForYou Medical has achieved an important milestone in strategic cooperation!

 

Novo Holdings, a leading global healthcare and life sciences investor, has completed a strategic minority investment in Huizhou ForYou Medical Devices Co.,Ltd. ("ForYou Medical"). GL Capital, one of China's leading healthcare-focused private equity firms, will remain the company's majority shareholder.

 

The investment reflects Novo Holdings' conviction in the long-term growth potential of the advanced wound care sector, and further highlights ForYou Medical's comprehensive strengths in technological innovation, regulatory capabilities, large-scale manufacturing, and international development. Moving forward, ForYou Medical will work together with Novo Holdings and GL Capital to continuously deepen its innovation capabilities, expand into international markets, and provide high-quality advanced wound care products and contract development and manufacturing organisation (CDMO) services to customers around the world.

 

Deepening Expertise in Advanced Wound Care and Continuously Building Global Capabilities

 

Since its founding in 2005, ForYou Medical has been deeply engaged in advanced wound care, focusing on the R&D, manufacturing, and global promotion of advanced wound care products. The company has gradually built an integrated platform spanning polymer materials and biomaterial research, product development, regulatory affairs, and large-scale manufacturing.

 

Supported by its long-accumulated technological capabilities, deep regulatory expertise, and manufacturing excellence, ForYou Medical provides customers with CDMO services across the entire product lifecycle. This supports customers from concept development and product registration to commercial production, accelerating the translation of innovations into the market. Today, ForYou Medical's advanced wound care products and solutions serve multiple leading healthcare companies across Europe, North America, and Asia.

 

Establishing this strategic partnership with Novo Holdings will further assist

ForYou Medical in expanding its global customer partnership network and continuously enhancing its research, development, regulatory, and manufacturing capabilities for the international market. The Global Advanced Wound Care Market Continues to Grow Advanced wound care is a structurally growing and important healthcare segment. Ageing populations, the increasing prevalence of chronic wounds, and the continued adoption of advanced treatment solutions are driving the continuous development of the global advanced wound care market.

 

As healthcare companies increasingly deepen their partnerships with specialist manufacturers, the value of specialized R&D and manufacturing partners in accelerating product innovation, broadening product portfolios, and improving operational efficiency becomes increasingly prominent. Consequently, the demand for high-quality CDMO partners continues to grow.

 

Jinwen Mo, CEO, ForYou Medical, said:

"We are pleased to welcome Novo Holdings as a strategic investor. Their deep experience across the global healthcare ecosystem, long-term investment approach and international network make them an excellent partner as we continue expanding our innovation capabilities and serving customers around the world. Together with GL Capital, we look forward to building on our strong foundation and creating long-term value for our customers, employees and partners."

 

Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, said:

"China continues to strengthen its position as a global centre for healthcare innovation and advanced manufacturing. At Novo Holdings, we are committed to partnering with exceptional companies that combine strong technological capabilities with international competitiveness and long-term growth potential. ForYou Medical exemplifies these qualities, and this investment reflects our confidence in the continued evolution of China's life sciences ecosystem."

 

Sean He, Partner and Head of China at Novo Holdings, added:

"ForYou Medical has established itself as a trusted manufacturing partner to many leading wound care companies through its strong product capabilities, regulatory expertise and consistent focus on quality. We look forward to working alongside the management team and GL Capital to support the company's continued international growth, strengthen its innovation capabilities and help expand its global customer partnerships."

 

Zhenfu Li, CEO, GL Capital, said:

"Since partnering with ForYou Medical, we have worked closely with management to strengthen the company's capabilities and accelerate its growth. We are delighted to welcome Novo Holdings as a like-minded long-term investor whose global healthcare expertise and international network will further support the company's next stage of development."

 

Looking ahead, ForYou Medical will continue to focus deeply on the advanced wound care sector. Rooted in technological innovation and manufacturing excellence, the company will consistently optimize its R&D, regulatory, and manufacturing systems while deepening global customer partnerships.

 

Leveraging Novo Holdings' global healthcare expertise and international network, alongside the long-term support of GL Capital, ForYou Medical will further accelerate its international growth and drive China's advanced wound care manufacturing capabilities into a broader global market.

 

About Novo Holdings

 Novo Holdings is a holding and investment company that manages the assets of the Novo Nordisk Foundation. Novo Holdings aims to generate attractive long-term returns on the assets of the Novo Nordisk Foundation to improve people’s health and the sustainability of society and the planet.

As a wholly-owned subsidiary of the Novo Nordisk Foundation, Novo Holdings manages its investment portfolio with a long-term value orientation. Novo Holdings is a leading global life sciences investor. In addition to broadly investing in equities, bonds, real estate, infrastructure assets, and private equity funds, it also invests in life science companies at all stages of development through its specialized Seed, Venture, Growth, Planetary Health, and Principal Investments teams. As of the end of 2025, Novo Holdings' total assets
under management reached EUR 93 billion.

 

About GL Capital

GL Capital is an investment firm focusing on controlling-stake projects and growth-stage enterprises in China's healthcare industry. Founded in 2010 by Mr. Li Zhenfu, the former President of Novartis China, the firm manages U.S. dollar-denominated and RMB-denominated private equity funds as well as hedge funds, with total assets under management (AUM) exceeding RMB 22 billion.

GL Capital is committed to becoming the most trustworthy partner for leading enterprises in the industry, continuously delivering excellent returns to its investors, and jointly promoting the sound development of China's healthcare industry. As the world's second-largest healthcare market, China, driven by factors such as structural reforms, population aging, and improved medical conditions, provides us with a steady stream of investment opportunities.

GL Capital focuses on investing in outstanding enterprises with long-term sustainable competitive advantages. We aim to collaborate with like-minded, visionary management teams to pursue excellence and create value together.